[{"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "1414.00", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106110930", "Name_of_Associated_Covered_Drug_or_Biological1": "Actos", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "825.99", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106110927", "Name_of_Associated_Covered_Drug_or_Biological1": "Actos", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "GlaxoSmithKline, LLC.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005449", "Total_Amount_of_Payment_USDollars": "92.20", "Date_of_Payment": "05/28/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "208680858", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "GlaxoSmithKline, LLC.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005449", "Total_Amount_of_Payment_USDollars": "1.08", "Date_of_Payment": "05/28/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "208680862", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE", "Research_Information_Link": "", "Context_of_Research": ""}]